ERBB2 and non-small cell lung carcinoma: Beyond NSCLC, the phase II DESTINY-PanTumor01 trial (NCT04639219) demonstrated promising activity in 102 patients with various solid tumors harboring specific activating HER2 mutations, showing an ORR of 29.4% (95% CI: 20.8–39.3) [100].